Lantheus Holdings, Inc. (LNTH) CFO John W. Crowley Sells 6,755 Shares
Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO John W. Crowley sold 6,755 shares of the stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Lantheus Holdings, Inc. (NASDAQ LNTH) traded up 0.56% on Tuesday, hitting $17.85. 293,620 shares of the stock were exchanged. The firm’s 50-day moving average is $17.64 and its 200-day moving average is $17.64. The company has a market cap of $666.70 million, a P/E ratio of 24.39 and a beta of 0.91. Lantheus Holdings, Inc. has a one year low of $7.65 and a one year high of $20.45.
Lantheus Holdings (NASDAQ:LNTH) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 EPS for the quarter, beating the consensus estimate of $0.24 by $0.18. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The business had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. During the same period in the prior year, the business earned $0.24 earnings per share. The business’s quarterly revenue was up 13.9% on a year-over-year basis. On average, equities analysts forecast that Lantheus Holdings, Inc. will post $1.12 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/lantheus-holdings-inc-lnth-cfo-john-w-crowley-sells-6755-shares/1637260.html.
Hedge funds have recently added to or reduced their stakes in the stock. Systematic Financial Management LP acquired a new stake in Lantheus Holdings during the first quarter valued at approximately $1,314,000. Royce & Associates LP acquired a new stake in Lantheus Holdings during the second quarter valued at approximately $4,896,000. Bank of New York Mellon Corp lifted its stake in Lantheus Holdings by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after purchasing an additional 4,084 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Lantheus Holdings during the second quarter valued at approximately $835,000. Finally, FNY Partners Fund LP acquired a new stake in Lantheus Holdings during the first quarter valued at approximately $174,000. 84.34% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have issued reports on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $22.00 target price (up from $18.00) on shares of Lantheus Holdings in a report on Wednesday, August 2nd. Zacks Investment Research cut shares of Lantheus Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, September 20th. Cantor Fitzgerald assumed coverage on shares of Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 target price for the company. Credit Suisse Group increased their target price on shares of Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Finally, BidaskClub cut shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Lantheus Holdings currently has an average rating of “Buy” and a consensus target price of $18.60.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.